50 results
Page 2 of 3
8-K
EX-99.1
g3o ipqs09y71rdir06f
25 Mar 21
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
8:31am
424B5
gaj6osnc6ckr62 1njy
12 Feb 21
Prospectus supplement for primary offering
9:00am
424B5
l228nj0krm3hxo5q
11 Feb 21
Prospectus supplement for primary offering
5:14pm
8-K
6k39epr2ml
4 Feb 21
Other Events
7:35am
8-K
EX-99.1
gnnprmgr hywsd66qlq
29 Oct 20
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
4:02pm
8-K
EX-99.1
4v4yfv3z8v6xwztpwu
30 Jul 20
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
6:41pm
8-K
EX-99.1
tp1gabh02qiyyi
30 Apr 20
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
4:07pm
424B5
aljsg62sv699w8v axb
20 Mar 20
Prospectus supplement for primary offering
5:17pm
8-K
EX-99.1
eox0qv1yllp
5 Mar 20
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
4:07pm
8-K
EX-99.1
mm9drscf 3jpnl5
3 Feb 20
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum
8:00am
8-K
EX-99.1
gfmdprr02e1o25js
9 Dec 19
Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy
6:30am
8-K
EX-99.1
oyf4au5zue 0ug
29 Oct 19
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
4:51pm
8-K
EX-99.1
6fslk0zq9
1 Aug 19
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
4:10pm
8-K
EX-99.1
pkjie9bycy
9 May 19
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
4:04pm